ADIPOQ and metabolic dysfunction-associated steatotic liver disease: Metformin treatment was for example shown to improve endothelium-dependent vasodilation and microvascular reactivity in humans with the metabolic syndrome [8,29], and to improve arterial stiffness in patients with nonalcoholic fatty liver disease, which was partly explained by an increase in circulating adiponectin levels [30].